Literature DB >> 11996891

Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells.

Henrik Lövborg1, Petra Martinsson, Joachim Gullbo, Sara Ekelund, Peter Nygren, Rolf Larsson.   

Abstract

The role of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) and the ADP-ribosylation inhibitor 3-aminobenzamide (3-ABA) in the cytotoxicity induced by the novel antitumoral cyanoguanidine CHS 828 was investigated in the human lymphoma cell line U-937 GTB. Exposing cells to CHS 828 and 3-ABA in combination resulted in a 100-fold higher IC(50) compared to exposure to CHS 828 alone. CHS 828 did not activate PARP, measured as PARP-activity and formation of poly(ADP-ribose). The ATP-levels and levels of extracellular acidification rate of cells exposed to CHS 828 in combination with 3-ABA were maintained for a longer period than for cells exposed to CHS 828 alone. To characterize the mode of cell death, caspase-3 activity and gross morphology were assessed. 3-ABA increased and delayed the caspase-3 activity in cells exposed to CHS 828. Cells exposed to high concentrations of CHS 828 showed a necrotic morphology, while high concentrations of CHS 828 in combination with 3-ABA switched the mode of cell death, generating an apoptotic morphology. The results indicate that the cytotoxicity and morphology induced by CHS 828 is not due to PARP activation but can be modulated by the ADP-ribosylation inhibitor 3-ABA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996891     DOI: 10.1016/s0006-2952(02)00890-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer.

Authors:  Shun-Lai Li; Chia-Hsin Huang; Chih-Chan Lin; Zih-Ning Huang; Jyh-Haur Chern; Hsiao-Yin Lien; Yong-Yi Wu; Chia-Hui Cheng; Chia-Yu Chang; Jiunn-Jye Chuu
Journal:  Invest New Drugs       Date:  2009-12-05       Impact factor: 3.850

2.  Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug.

Authors:  Henrik Lövborg; Robert Burman; Joachim Gullbo
Journal:  BMC Res Notes       Date:  2009-06-29

3.  The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.

Authors:  Mark Watson; Anne Roulston; Laurent Bélec; Xavier Billot; Richard Marcellus; Dominique Bédard; Cynthia Bernier; Stéphane Branchaud; Helen Chan; Kenza Dairi; Karine Gilbert; Daniel Goulet; Michel-Olivier Gratton; Henady Isakau; Anne Jang; Abdelkrim Khadir; Elizabeth Koch; Manon Lavoie; Michael Lawless; Mai Nguyen; Denis Paquette; Emilie Turcotte; Alvin Berger; Matthew Mitchell; Gordon C Shore; Pierre Beauparlant
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

4.  The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis.

Authors:  P Martinsson; S Ekelund; P Nygren; R Larsson
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.